Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NRIX with free AI briefings, catalyst countdowns, and dilution alerts.

NRIX · Nurix Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.1B Cash on Hand
CF+ Cash Runway
Follow NRIX by email Get an email when NRIX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NRIX, unsubscribe in one click. Privacy

📣 What NRIX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Bexobrutideg (NX-5948) B-cell Lymphoma Phase 3 · NCT07516093 Recruiting
Drug Product De-TIL-0255 Platinum-resistant Ovarian Cancer Phase 1 · NCT05107739 Terminated
Esomeprazole Healthy Volunteer Phase 1 · NCT06717269 Completed
CBL-B Inhibitor NX-1607 Ovarian Cancer, Epithelial Phase 1 · NCT05107674 Recruiting
Zelebrudomide (NX-2127) Chronic Lymphocytic Leukemia (CLL) Phase 1 · NCT04830137 Recruiting
Quinidine Healthy Volunteer Phase 1 · NCT06717269 Completed
Rosuvastatin Healthy Volunteer Phase 1 · NCT06717269 Completed

Also used in these trials (approved or third-party drugs, not NRIX's own candidates): Pirtobrutinib, Obinutuzumab, Rituximab, Venetoclax, Digoxin, Famotidine, Midazolam Hydrochloride, Paclitaxel.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NRIX holds $1.1B in cash and short-term investments (as of Aug 31, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 14 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NRIX files for a raise →

👥 Who Owns NRIX

Insiders 0.2% Institutions (302 holders) 99.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Baker Bros. Advisors LP Institution (13G, 5%+) 7,527,996 6.89% 2025-12-31
Vestal Point Capital, LP Institution (13G, 5%+) 7,025,000 6.43% 2026-09-30
Deep Track Capital, LP Institution (13G, 5%+) 6,000,000 5.49% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 5,202,025 4.76% 2026-06-30
Gwenn Hansen
Chief Scientific Officer · +187,434 options
Insider 123,452 0.11% 2026-10-30
Houte Hans van
Chief Financial Officer · +129,480 options
Insider 42,745 0.04% 2026-11-04
Julia P Gregory
Director · +31,250 options
Insider 10,750 0.01% 2026-10-14
Christine Ring
Chief Legal Officer · +234,945 options
Insider 4,406 0.00% 2026-11-02

Share count 109,249,814 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NRIX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NRIX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.